OS was significantly longer for patients whose tumor expressed low levels of K-RAS and miR-25-3p and a high level of miR-18a-3p than for those whose tumor expressed high levels of K-RAS and miR-25-3p and a low level of miR-18a-3p (median OS (months), training set: high K-RAS=20.73, low K-RAS=31.49; validation set: high K-RAS=14.98, low K-RAS=31.8; training set, P=0.0292; validation set, P=0.0107; Figure 5c). The gene discussed is KRAS; the disease is neoplasm.